Ysios Capital

Ysios Capital is a venture capital firm founded in 2008 that invests globally in private biotechnology companies developing novel therapeutics for areas of critical unmet medical need. The firm has raised three funds, with more than €400 million in assets under management, and its portfolio spans biotech companies across Europe and the United States. Investment activity is concentrated in therapeutic drug development, with sector interests including oncology, neuroscience and genetic disease.

The firm's stated approach is to back exceptional teams and pioneering science, with the objective of converting promising research into medical treatments. Its remit is mission-driven rather than diversified: the investment focus is narrow by design, targeting therapeutic areas where existing options are inadequate. Portfolio reach across both European and US biotech clusters reflects the geographic concentration of early-stage drug development talent and capital.

Ysios Capital operates from offices in San Sebastián and Barcelona. Its team combines scientific, financial and entrepreneurial expertise - a composition that reflects the technical diligence requirements of preclinical and clinical-stage therapeutics investing. The firm describes its investment activity as aiming to have a positive impact on patients and society.